Target Gene/Pathway Pathway / Gene
Search results
| No. | KEGG PATHWAY On map, Yellow: Drug target, Red: All disease-related | KEGG GENES | KEGG DRUG | DrugBank | Disease ID |
|---|---|---|---|---|---|
| 1 | Chagas disease 💬 28 genes, 44 drugs (DrugBank) and 77 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Otelixizumab Otelixizumab 💬
| Otelixizumab | 046 [1] 46 💬
|
| 2 | Chagas disease 💬 28 genes, 44 drugs (DrugBank) and 77 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Visilizumab Visilizumab 💬
| Visilizumab | 096 [2] 96, 97 💬
|
| 3 | Epstein-Barr virus infection 💬 44 genes, 62 drugs (DrugBank) and 66 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Otelixizumab Otelixizumab 💬
| Otelixizumab | 046 [1] 46 💬
|
| 4 | Epstein-Barr virus infection 💬 44 genes, 62 drugs (DrugBank) and 66 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Visilizumab Visilizumab 💬
| Visilizumab | 096 [2] 96, 97 💬
|
| 5 | Hematopoietic cell lineage 💬 32 genes, 70 drugs (DrugBank) and 90 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Otelixizumab Otelixizumab 💬
| Otelixizumab | 046 [1] 46 💬
|
| 6 | Hematopoietic cell lineage 💬 32 genes, 70 drugs (DrugBank) and 90 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Visilizumab Visilizumab 💬
| Visilizumab | 096 [2] 96, 97 💬
|
| 7 | Human immunodeficiency virus 1 infection 💬 41 genes, 43 drugs (DrugBank) and 89 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Otelixizumab Otelixizumab 💬
| Otelixizumab | 046 [1] 46 💬
|
| 8 | Human immunodeficiency virus 1 infection 💬 41 genes, 43 drugs (DrugBank) and 89 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Visilizumab Visilizumab 💬
| Visilizumab | 096 [2] 96, 97 💬
|
| 9 | Human T-cell leukemia virus 1 infection 💬 37 genes, 59 drugs (DrugBank) and 84 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Otelixizumab Otelixizumab 💬
| Otelixizumab | 046 [1] 46 💬
|
| 10 | Human T-cell leukemia virus 1 infection 💬 37 genes, 59 drugs (DrugBank) and 84 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Visilizumab Visilizumab 💬
| Visilizumab | 096 [2] 96, 97 💬
|
| 11 | Measles 💬 40 genes, 44 drugs (DrugBank) and 52 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Otelixizumab Otelixizumab 💬
| Otelixizumab | 046 [1] 46 💬
|
| 12 | Measles 💬 40 genes, 44 drugs (DrugBank) and 52 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Visilizumab Visilizumab 💬
| Visilizumab | 096 [2] 96, 97 💬
|
| 13 | PD-L1 expression and PD-1 checkpoint pathway in cancer 💬 34 genes, 51 drugs (DrugBank) and 92 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Otelixizumab Otelixizumab 💬
| Otelixizumab | 046 [1] 46 💬
|
| 14 | PD-L1 expression and PD-1 checkpoint pathway in cancer 💬 34 genes, 51 drugs (DrugBank) and 92 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Visilizumab Visilizumab 💬
| Visilizumab | 096 [2] 96, 97 💬
|
| 15 | Primary immunodeficiency 💬 11 genes, 23 drugs (DrugBank) and 26 diseases |
CD3D [2] CD3D, CD3E 💬
|
Otelixizumab Otelixizumab 💬
| Otelixizumab | 046 [1] 46 💬
|
| 16 | Primary immunodeficiency 💬 11 genes, 23 drugs (DrugBank) and 26 diseases |
CD3D [2] CD3D, CD3E 💬
|
Visilizumab Visilizumab 💬
| Visilizumab | 096 [2] 96, 97 💬
|
| 17 | T cell receptor signaling pathway 💬 34 genes, 46 drugs (DrugBank) and 80 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Otelixizumab Otelixizumab 💬
| Otelixizumab | 046 [1] 46 💬
|
| 18 | T cell receptor signaling pathway 💬 34 genes, 46 drugs (DrugBank) and 80 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Visilizumab Visilizumab 💬
| Visilizumab | 096 [2] 96, 97 💬
|
| 19 | Th1 and Th2 cell differentiation 💬 33 genes, 37 drugs (DrugBank) and 70 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Otelixizumab Otelixizumab 💬
| Otelixizumab | 046 [1] 46 💬
|
| 20 | Th1 and Th2 cell differentiation 💬 33 genes, 37 drugs (DrugBank) and 70 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Visilizumab Visilizumab 💬
| Visilizumab | 096 [2] 96, 97 💬
|
| 21 | Th17 cell differentiation 💬 43 genes, 66 drugs (DrugBank) and 97 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Otelixizumab Otelixizumab 💬
| Otelixizumab | 046 [1] 46 💬
|
| 22 | Th17 cell differentiation 💬 43 genes, 66 drugs (DrugBank) and 97 diseases |
CD3D [3] CD3D, CD3E, CD3G 💬
|
Visilizumab Visilizumab 💬
| Visilizumab | 096 [2] 96, 97 💬
|